Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Danish Pre-HCQ COVID Dialysis Study
Sponsor: Nicholas Carlson
Summary
Hydroxychloroquine has been shown to inhibit replication of SARS-CoV-2 in vitro. The presented multicenter parallel-group open-label randomized clinical trial aims to investigate the efficacy of prophylactic hydroxychloroquine on mitigation of risk of hospitalization due to COVID-19 in patients with end-stage renal disease.
Official title: The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for Prevention of COVID19 in Dialysis-treated Patients With End-stage Renal Disease - A Multicenter Parallel-group Open Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2020-04-10
Completion Date
2020-10-01
Last Updated
2026-05-19
Healthy Volunteers
No
Conditions
Interventions
Hydroxychloroquine
Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
Locations (3)
Rigshospitalet
Copenhagen, Copenhagen, Denmark
Herlev Hospital
Herlev, Herlev, Denmark
North Zealand Hospital
Hillerød, Hillerød, Denmark